Abstract: A multilayer microencapsulated lactic bacteria and bifidobacteria, preferably bacteria with probiotic activity, and the use thereof to prepare a food product, supplement product, medical device or pharmaceutical composition or water- and/or fruit-based beverage are described. A process for preparing multilayer microencapsulated lactic bacteria and bifidobacteria, preferably bacteria with probiotic activity is described. A food product is described selected from water, water- and/or fruit-based beverages, milk, fresh whole milk, partially skimmed milk, powdered milk, cheese, fresh cheese, aged cheese, grated cheese, butter, margarine, yogurt, cream, milk- and chocolate-based custards, custards for sweets, jams and oily suspensions having bacteria, preferably multilayer microencapsulated lactic bacteria and bifidobacteria with probiotic activity.
Abstract: The present disclosure refers to a material impermeable to water vapor and oxygen for packaging dietary products, cosmetics and medicinal specialities. In particular, the present disclosure refers to primary packaging in the form of blister packs or sachets, which comes into direct contact with the formulations of medicinal specialities and dietary products and cosmetics, such as, for example, tablets, pills, pessaries, powders, granules, suppositories, rigid capsules and soft capsules (also known as soft gel capsules).
Abstract: The present disclosure refers to a composition with N-acetylcysteine and/or lysozyme; or N-acetylcysteine and microencapsulated gastroprotected lysozyme with pro biotic bacteria for use in the pharmacological treatment of gastric hyperacidity. Said composition is capable of restoring the stomach's own barrier effect, which is lost during the pharmacological treatment of gastric hyperacidity, and of minimizing the secondary effects due to said pharmacological treatment.
Abstract: The present disclosure refers to a material impermeable to water vapour and oxygen for packaging dietary products, cosmetics and medicinal specialities. In particular, the present disclosure refers to primary packaging in the form of blister packs or sachets, which comes into direct contact with the formulations of medicinal specialities and dietary products and cosmetics, such as, for example, tablets, pills, pessaries, powders, granules, suppositories, rigid capsules and soft capsules (also known as soft gel capsules).